![](/wp-content/uploads/2024/06/Screenshot-2024-06-26-at-3.26.55%E2%80%AFPM.png)
$599
Novo’s Ocedurenone CLARION-CKD Trial Fails; NeuroBo Doses First Patient in MAD Ph1 Obesity Trial; Another Generic Liraglutide FDA Approval
Three cardiometabolic-related news items have been observed: Novo Nordisk announced its CLARION-CKD Ph3 trial evaluating ocedurenone (nsMRA) failed to meet its primary endpoint (view CT.gov record; view press release); NeuroBo Pharmaceuticals announced it dosed first patients in the Part 2 MAD portion of its Ph1 trial of DA-1726 for obesity (view CT.gov record; view press release); and Hanyu Pharmaceuticals (and Hikma) announced its liraglutide ANDA has been granted tentative approval (view press release). Below, FENIX provides highlights and insights for the respective news items.